share_log

Truist Securities Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $24

Benzinga ·  Jun 21, 2023 12:56

Truist Securities analyst Joon Lee maintains Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and raises the price target from $22 to $24.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment